The Product Development for Vaccines Advisory Committee (PDVAC) provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies. Its remit includes the prioritisation of target pathogens for vaccine and/or monoclonal antibody development and technology platforms, in addition to oversight of the development of preferred product characteristics (PPCs), technical/R&D roadmaps, full vaccine value assessments and consultations on product development pathways.
The 2025 meeting will take place in Geneva from 6-8 October (open meeting) and 9 October (closed meeting).
Meeting materials will be made available here in due course.